【摘要】 目的:评价时间分辨荧光免疫分析(TRFIA)技术检测血清CA15-3、CEA在乳腺疾病诊断与治疗中的应用价值。方法:应用TRFIA技术检测正常对照组(57例)、乳腺增生组(206例)、乳腺良性肿瘤组(136例)、乳腺癌无复发或无转移组(89例)及乳腺癌复发或转移组(39例)患者血清CA15-3、CEA含量。结果:血清CA15-3、CEA含量,正常对照组、乳腺增生组、乳腺良性肿瘤组3组间比较差异均无显著性(P>0.05),但乳腺癌无复发或无转移组含量均明显高于前3组(P<0.05),乳腺癌有复发或转移组术前均明显高于前3组(P<0.01)及乳腺癌无复发或无转移组术前(P<0.05);乳腺癌术后3个月与前3组比较差异均无显著性(P>0.05),但均明显低于乳腺癌无复发或无转移组术前(P<0.05)及乳腺癌有复发或转移组(P<0.01)。结论:无创伤性血清CA15-3可作为乳腺疾病性质、术后疗效判定及随访的指标。更多还原

【Abstract】 Objective To evaluate the application values of time-resolves fluroimmunoassay(TRFIA) technique for CA15-3 and CEA detection in mammary gland diseases.Methods TRFIA was used to detect the serum concentrations of CA15-3 and CEA in normal control group(n=57),hyperplasia group(n=206),benign mammary neoplasm group (n=136),mammary cancer with out recurrence or metastasis group(n=89) and mammary cancer with recurrence or metastasis group(n=39).Results There were no significant differences of CA15-3 and CEA serum concentrations between control group,mammary hyperplasia group and benign mammary neoplasm group(P>0.05).However,the CA15-3 and CEA concentrations in mammary cancer without recurrence or metastasis group were significantly higher than those in the former three groups(P<0.05).Also,the CA15-3 and CEA concentrations in mammary cancer with recurrence or metastasis group were remarkably higher than those in the former three groups(P<0.01) and mammary cancer without recurrence or metastasis group(P<0.05).While CA15-3 and CEA concentrations in the 3-month post-operation group showed no significant difference with those in the former three groups(P>0.05),though,were distinctly lower than those in the mammary cancer without or with recurrence or metastasis groups(P<0.05,P<0.01).Conclusion The atraumatic detection of CA15-3 and CEA may be used as indexes in diagnosis,therapy,and curative effect estimation post-operation and following-up observation for mammary diseases.更多还原